| Course | NR 603 Advanced Clinical Diagnosis and Practice across the Lifespan Practicum |
|---|---|
| Week | 6 |
| Paper type | Case study analysis |
| Length | About 1,130 words, 4 pages |
| Format | APA 7 student paper |
| School | Chamberlain University |
| Program | MSN, Family Nurse Practitioner (FNP) |
| Updated | October 2026 |
Free sample paper for NR 603 Week 6
Case Study Analysis: A Gout Flare in a 71-Year-Old With Kidney Disease, Heart Failure, Atrial Fibrillation on Apixaban and Diltiazem, Where Every First-Line Choice Collides With Something
Student Name
College of Nursing, Chamberlain University
NR 603: Advanced Clinical Diagnosis and Practice across the Lifespan Practicum
Instructor Name
Month Day, Year
Case Study Analysis: A Gout Flare in a 71-Year-Old With Kidney Disease, Heart Failure, Atrial Fibrillation on Apixaban and Diltiazem, Where Every First-Line Choice Collides With Something
The Case
A 71-year-old retired mail carrier presents with a hot, swollen, painful left knee for two days, unable to bear weight comfortably. Two previous gout attacks in the big toe, the last a year ago. Temperature 37.6 °C. Knee warm, swollen, with an effusion; range limited by pain. Joint aspiration in clinic: cloudy fluid, needle-shaped crystals under the microscope, white cell count 22,000, Gram stain negative, culture sent.
Problem list: chronic kidney disease stage 3b, estimated glomerular filtration rate 38; heart failure, ejection fraction preserved; atrial fibrillation on anticoagulation; type 2 diabetes; hypertension.
Medicines: apixaban 5 mg twice daily; diltiazem extended release 180 mg daily for rate control; furosemide 40 mg daily; metformin 500 mg twice daily; lisinopril 10 mg daily.
Lives with a spouse who does not drive; the nearest pharmacy is 15 minutes away by bus.
The Problem List as Evidence
The diagnosis is the easy part: crystals in the fluid confirm gout, and a negative Gram stain with a culture pending makes infection less likely, though not excluded until the culture is back. The work is in what the patient already has.
The Standard Approach, Stated
For an acute gout flare, the American College of Rheumatology recommends any of three first-line choices: a nonsteroidal anti-inflammatory medicine, colchicine or a glucocorticoid, chosen according to the patient's other conditions (FitzGerald et al., 2020).
Where the Standard Collides With This Patient
Nonsteroidal anti-inflammatory medicine. Collides with three things: the kidneys, since these medicines reduce kidney blood flow and can cause acute kidney injury at an eGFR of 38; the heart failure, since they cause fluid retention; and apixaban, since together they raise bleeding risk. Ruled out.
Colchicine. Collides with the kidneys and with diltiazem. The kidneys help clear colchicine, and diltiazem slows its breakdown through a liver enzyme pathway, which raises colchicine levels. Low-dose colchicine was as effective as high-dose for acute gout with fewer side effects in a trial (Terkeltaub et al., 2010), but in this patient even the low dose would need further reduction, and toxicity can include diarrhea, low blood counts and muscle damage. Possible only at a reduced dose with close monitoring.
Oral glucocorticoid. Collides with diabetes, since prednisone raises blood sugar for several days, and with heart failure, since it can cause fluid retention. Not ruled out, but carries costs.
Joint injection of a glucocorticoid. A single injection into the knee treats the flare where it is, with much less effect on blood sugar and fluid than a course of tablets. Requires that infection has been reasonably excluded.
The Chosen Plan and Its Cost
Today: joint aspiration done; inject triamcinolone 40 mg into the left knee, once the Gram stain is negative, with the culture pending. If the culture grows bacteria, the plan changes to treatment of a septic joint in hospital.
Pain: acetaminophen 1 gram up to three times a day. Ice and rest for 48 hours.
No colchicine for this flare, given the diltiazem interaction and kidney function.
No nonsteroidal anti-inflammatory medicine.
Cost of this choice: a small rise in blood sugar for 24 to 48 hours; a small risk of joint infection from the injection; relying on a single procedure rather than a medicine the patient can take at home if the flare returns.
Monitoring That Means Something
Blood sugar: the patient checks fingerstick glucose morning and evening for three days; call if above 300 mg/dL.
Weight: weigh each morning for a week, as the heart failure plan already asks; a gain of more than a kilogram overnight, or two over the week, means a call.
Knee: call the same day if fever rises above 38 °C, the knee becomes more painful after 24 hours or redness spreads.
Culture result: the clinic calls the patient within 48 hours.
Kidney function: basic metabolic panel in one week, since the illness and reduced drinking can affect the kidneys.
Who Is at Home to Help
The spouse can help with glucose checks and weights but cannot drive. The clinic arranged for the pharmacy to deliver acetaminophen and glucose strips. The patient's adult child, who lives 30 minutes away, will drive to the follow-up visit.
Why Not Prednisone Instead of the Injection
A short course of oral prednisone would be reasonable for a patient with several joints involved. For a single large joint, the injection treats the flare with a fraction of the drug reaching the rest of the body. With diabetes and heart failure, both sensitive to steroids, a smaller total dose is safer. If the flare had involved several joints, the comparison would favor a short, low-dose oral course with closer glucose and weight checks.
What the Beers Criteria Add
Nonsteroidal anti-inflammatory medicines appear in the Beers Criteria among drugs that older adults with heart failure or weak kidneys should avoid (2023 American Geriatrics Society Beers Criteria Update Expert Panel, 2023). For this patient, that guidance and the bleeding risk with apixaban make the decision easy. The harder decisions are between colchicine and steroids, where neither is free of cost.
What the Patient Was Told
The patient was told why the usual tablets for gout were not safe this time, that the injection should ease the knee within one to two days and that the blood sugar would probably rise for a day or two. The patient asked whether the gout would keep coming back. I said that after three attacks, a daily medicine to lower uric acid was worth discussing once this flare settled.
The Culture Result
Two days later, the joint fluid culture showed no growth, which supports gout as the only cause and makes the injection decision safe in retrospect. Had it grown bacteria, the patient would have been admitted for drainage and intravenous antibiotics, and the steroid injection would have been a mistake. That risk is why the injection waited for the Gram stain and why the culture was sent before it.
After the Flare
The patient has now had three flares. Long-term urate-lowering treatment is indicated. Allopurinol can be started at a low daily dose suited to an eGFR of 38, with the ACR guideline recommending starting low and increasing gradually (FitzGerald et al., 2020). That decision is made at follow-up in two weeks, when the flare has settled, and will need its own review of interactions.
References
2023 American Geriatrics Society Beers Criteria Update Expert Panel. (2023). American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society, 71(7), 2052-2081. https://doi.org/10.1111/jgs.18372
FitzGerald, J. D., Dalbeth, N., Mikuls, T., Brignardello-Petersen, R., Guyatt, G., Abeles, A. M., Gelber, A. C., Harrold, L. R., Khanna, D., King, C., Levy, G., Libbey, C., Mount, D., Pillinger, M. H., Rosenthal, A., Singh, J. A., Sims, J. E., Smith, B. J., Wenger, N. S., ... Neogi, T. (2020). 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care & Research, 72(6), 744-760. https://doi.org/10.1002/acr.24180
Terkeltaub, R. A., Furst, D. E., Bennett, K., Kook, K. A., Crockett, R. S., & Davis, M. W. (2010). High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis & Rheumatism, 62(4), 1060-1068. https://doi.org/10.1002/art.27327
What the NR 603 Week 6 assignment asks for
The Week 6 analysis spends its length on interactions rather than diagnosis. By this point in the term the diagnosis is often the easy part; the work is in what the patient already takes, what the kidneys will tolerate, what other conditions do to the first-line choice and who is at home to help. Name the collision plainly: the drug indicated for the new problem worsens an old one, or the monitoring is impossible at home. Choose a plan and state its cost. Make monitoring specific. Most rubrics mark down a plan lifted straight from a guideline, a comorbidity mentioned once and never again and a medicine list read as a list rather than as interactions.
How this NR 603 Week 6 example is built
The sample confirms gout by joint fluid crystals with a culture pending. It states the American College of Rheumatology's three first-line options, then shows each colliding: anti-inflammatories with kidney function, heart failure and apixaban; colchicine with kidney clearance and diltiazem; oral steroids with diabetes and fluid. A knee injection is chosen once the Gram stain is negative, with its costs stated. Monitoring covers glucose, weight, the knee, the culture and kidney function, each with a threshold. Home help is arranged. Sections compare the injection with prednisone, cite the Beers Criteria, report the culture and plan long-term treatment. Margin notes show where each collision and the chosen plan earn credit.
Reading the NR 603 Week 6 grading rubric
The costly answer is the clean one, a guideline plan that is correct in general and dangerous here; this analysis shows each first-line option failing for a reason specific to the patient. A comorbidity that appears once and disappears loses the next share, while every condition shapes a decision here. Reading the medicine list without interactions costs a row, and the diltiazem and colchicine interaction is named. Monitoring with no threshold loses marks, and each item here has one. Planning around who is at home earns the final criterion. Reporting the culture result shows why the injection waited for the stain. Comparing the injection with oral steroids shows the choice was weighed.
Common NR 603 Week 6 mistakes, and how to avoid them
Weak NR 603 Week 6 analyses copy the guideline's first-line treatment without checking it against the patient. Others list the comorbidities in the case summary and never return to them. Many miss an interaction between a new drug and one already taken. Monitoring plans are often vague. Few consider who will help at home. State the standard approach, test each option against every condition and medicine, choose one with its cost and set monitoring with thresholds the patient can act on. With your own patient, start from the problem list and every medicine, and the same collision-by-collision sample can follow. Arrange help at home before the patient leaves.
Get a NR 603 Week 6 example written to your instructions
Send the Week 6 case and the rubric your section is marking against, and a custom example is written to them and returned inside 24 to 48 hours. The first one is free. Where your classroom lets you bring a case of your own, send the problem list and the medications with it.
More NR 603 papers and FNP samples
- NR 603 Week 1: Undifferentiated Complaint Post
- NR 603 Week 2: Undifferentiated Case Analysis
- NR 603 Week 3: Results Visit SOAP Note
- NR 603 Week 4: Diagnostic Reasoning Write-Up
- NR 603 Week 5: Referral Rationale
- NR 603 Week 7: Complex Case Write-up
- NR 603 Week 8: Synthesis Paper
- NR 602 Week 6: Pediatric SOAP Note
- NR 511 Week 6: Chronic Care Note, Diabetes Reopened
- NR 601 Week 6: Patient-Goal Care Plan
- NR 566 Week 6: Geriatric Medication Review
NR 603 Week 6 questions, answered
Which condition should the paper treat as primary?
Usually the one driving the current presentation, but the choice needs saying out loud. Papers that leave it implicit end up arguing with themselves, treating one problem in the plan and another in the discussion. Naming the primary problem and stating that the others constrain rather than direct the plan keeps the analysis coherent.
Is it acceptable to depart from a guideline?
Yes, when the departure is argued. Guidelines describe populations and this patient is one person with kidneys, a medication list and a budget. A paper that explains why the recommended agent is wrong here and what replaces it is doing graduate work. A paper that departs silently reads as an error the writer did not notice.
How much of the paper should cover social factors?
Enough to change something. Cost, transport, literacy and who is at home matter when they alter the plan, and a sentence saying the patient faces barriers alters nothing. If the follow up interval was set by how often this person can reach a lab, say that, and the social detail becomes part of the clinical reasoning.
Where can I find a free NR 603 Week 6 sample paper?
The full case study analysis of a gout flare complicated by kidney disease, heart failure and anticoagulation is published on this page.
Why is colchicine avoided in the NR 603 Week 6 analysis?
The kidneys help clear it and diltiazem slows its breakdown, so levels would rise and toxicity would be likely even at a low dose.